Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

US Pharmacopeia in 2026: USP–NF Standards, Monographs, General Chapters, and Pharmaceutical Compliance

Explore how USP-NF standards, monographs, General Chapters, and reference standards support pharmaceutical quality testing and GMP compliance. Learn which compendial requirements are mandatory, how teams manage updates, and what evidence laboratories should maintain for inspection readiness.
  • Blog, Quality Management System
Pharmaceutical quality laboratory applying USP monographs, reference standards, analytical testing, and GMP compliance controls.

ISO 9000 in Pharma Industry in 2026: QMS Principles, ISO 9001, GMP Alignment and Implementation Guide

Explore how ISO 9000 principles support pharmaceutical quality systems, strengthen GMP compliance, and connect with ISO 9001 and ICH Q10. Learn how quality teams can apply process-based management, risk-based decisions, and continual improvement to build inspection-ready operations.
  • Blog, Quality Management System
Pharmaceutical quality management system showing GMP compliance, process approach, quality controls, and continual improvement across regulated manufacturing operations.

ISO 9001 in Pharma Industry in 2026: Requirements, GMP Compliance, ICH Q10, and Certification Guide

Explore how ISO 9001 certification supports pharmaceutical quality management, complements GMP compliance and ICH Q10, and strengthens risk management, CAPA, documentation, and continual improvement. Learn what auditors review and which evidence matters most during quality-system assessments.
  • Blog, Quality Management System
Pharmaceutical quality management system showing GMP compliance, quality risk management, CAPA, and inspection-ready documentation.

ICH Guidelines for Pharmacovigilance in 2026: E2A–E2F, ICSR Reporting, PBRER, and Risk Management

Explore how the ICH E2 series connects expedited safety reporting, electronic ICSR transmission, PBRERs, DSURs, and pharmacovigilance planning. This guide also explains regional implementation, inspection evidence, and the controls needed to maintain reliable safety operations.
  • Blog, Quality Management System
Pharmaceutical compliance dashboard showing ICH E2B R3 data exchange, individual case safety reports, periodic benefit-risk evaluation, DSUR preparation, and inspection evidence.

ICSR in Pharmacovigilance in 2026: Case Processing, E2B(R3), Reporting Timelines, and Compliance Guide

Explore how safety teams manage ICSR validity, day zero, MedDRA coding, seriousness assessment, E2B(R3) reporting, follow-up, and duplicate cases. This guide also explains reporting timelines, inspection evidence, and the controls needed for reliable pharmacovigilance compliance.
  • Blog, Quality Management System
Pharmacovigilance dashboard showing ICSR validity criteria, seriousness assessment, duplicate case management, reporting timelines, and EudraVigilance submission controls.

Pharmacovigilance System Master File in 2026: PSMF Requirements, EU GVP Module II, QPPV, and Inspection Readiness

Explore PSMF requirements, structure, maintenance, and inspection readiness under EU GVP Module II. This article explains QPPV responsibilities, annex control, computerised systems, audit evidence, and change management practices that help drug safety teams prepare for regulatory inspections.
  • Blog, Quality Management System
PSMF structure showing QPPV responsibilities, safety data systems, PSMF annexes, quality controls, audits, and inspection-ready documentation.

Pharma Quality Systems in 2026: ICH Q10, GMP Compliance, and PQS Guide

Discover how pharma quality systems based on ICH Q10 strengthen GMP compliance through CAPA, change management, quality risk management, and management review. Learn how an effective pharmaceutical quality system improves inspection readiness, prevents recurring failures, and supports continual improvement.
  • Blog, Quality Management System
Pharmaceutical quality management system infographic showing ICH Q10 elements, CAPA system, quality risk management, and GMP quality controls in pharma manufacturing.

Risk Management Plan in Pharmacovigilance in 2026: EMA RMP and Safety Monitoring Guide

This guide explains how an EMA risk management plan supports safety specification, additional pharmacovigilance activities, and effective risk minimisation measures. It also shows how lifecycle updates help teams manage important identified risks and maintain a positive benefit-risk balance.
  • Blog, Quality Management System
Illustration of an EU risk management plan showing safety specification, important identified risks, lifecycle monitoring, and additional pharmacovigilance activities.

Rechallenge in Pharmacovigilance in 2026: Causality Assessment and Drug Safety

This article explains how positive and negative drug rechallenge findings strengthen causality assessment, improve Individual Case Safety Report documentation, and support regulatory decision-making under WHO-UMC, Naranjo, EMA GVP Module VI, and ICH E2D frameworks worldwide.
  • Blog, Quality Management System
Drug safety specialist reviewing positive and negative rechallenge outcomes, adverse drug reaction data, and Individual Case Safety Report documentation.

Dechallenge in Pharmacovigilance in 2026: Causality Assessment and Safety Signal Review

Explore how dechallenge in pharmacovigilance supports causality assessment, safety signal review, and regulatory reporting. Learn how positive dechallenge, negative dechallenge, and rechallenge findings help pharmaceutical teams evaluate adverse drug reactions and improve Individual Case Safety Reports.
  • Blog, Quality Management System
Pharmacovigilance causality assessment workflow showing adverse drug reaction evaluation, dechallenge outcomes, and Individual Case Safety Report review